Oncology Brothers: Practice-Changing Cancer Discussions Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
Jul 24, 2025
Dr. Anand Patel, a hematologist and medical director at the University of Chicago, joins the hosts to dive deep into acute myeloid leukemia (AML). He discusses the current standards for diagnosing and risk stratifying AML patients. The conversation highlights the significance of molecular profiling in tailoring treatment plans. They explore induction chemotherapy options, including the classic 7+3 regimen and innovative therapies like venetoclax for unfit patients. Finally, they touch on the promise of emerging targeted therapies aimed at improving patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Act Fast On Suspected AML/APL
- If acute leukemia is suspected, verify circulating blasts, APL concern, and white count before transfer.
- Administer ATRA promptly if APL is possible and arrange transfer for marrow and definitive testing.
Minimum Diagnostic Workup
- Send a bone marrow biopsy with flow, broad molecular panel, conventional karyotype, and FISH for core binding factors and KMT2A.
- Repeat or supplement testing from peripheral blood if blasts >5% to speed actionable results.
Molecular Profiling Drives Strategy
- Broad molecular profiling guides immediate treatment intensity and long-term consolidation/transplant decisions.
- Use ELN22 for intensive chemo and ELN24 for lower-intensity therapy risk stratification.